Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 6.82B P/E - EPS this Y 38.10% Ern Qtrly Grth -
Income -239.78M Forward P/E -66.70 EPS next Y 30.40% 50D Avg Chg 3.00%
Sales 631.73M PEG -0.31 EPS past 5Y - 200D Avg Chg 26.00%
Dividend N/A Price/Book 8.50 EPS next 5Y 51.40% 52W High Chg -8.00%
Recommedations 2.30 Quick Ratio 4.25 Shares Outstanding 106.44M 52W Low Chg 147.00%
Insider Own 2.18% ROA -11.95% Shares Float 104.40M Beta 1.85
Inst Own 96.99% ROE -31.61% Shares Shorted/Prior 7.81M/10.42M Price 58.70
Gross Margin 64.70% Profit Margin -37.96% Avg. Volume 943,083 Target Price 27.43
Oper. Margin -27.26% Earnings Date Oct 31 Volume 1,672,968 Change -5.70%
About 10x Genomics, Inc.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

10x Genomics, Inc. News
11/20/24 If RFK Jr. Cuts Science Funding, These Instrument Makers May Suffer
11/19/24 10x Genomics, Inc. (TXG): Among the Best Genomics Stocks to Buy Right Now
11/07/24 10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference
11/01/24 Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts
10/31/24 TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative
10/30/24 Q3 2024 10X Genomics Inc Earnings Call
10/30/24 10x Genomics Inc (TXG) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...
10/29/24 10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10/29/24 10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
10/29/24 10x Genomics: Q3 Earnings Snapshot
10/29/24 10x Genomics Reports Third Quarter 2024 Financial Results
10/29/24 Zacks Industry Outlook Medical Systems, 10x Genomics and Omnicell
10/28/24 Lower Instruments Sales to Hurt TXG Q3 Earnings, Prelim Sales Down
10/28/24 3 Medical Info Systems Stocks to Gain From Healthcare Digitization
10/23/24 10x Genomics (TXG) Upgraded to Strong Buy: Here's Why
10/23/24 American Well Corporation (AMWL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
10/22/24 10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
10/15/24 10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches
10/10/24 These Stocks Moved the Most Today: Tesla, Super Micro, AMD, and More
10/10/24 Sector Update: Health Care Stocks Retreat Late Afternoon
TXG Chatroom

User Image jschwab1978 Posted - 2 hours ago

$TXG https://www.insidermonkey.com/blog/10-best-genomics-stocks-to-buy-right-now-1392600/8/

User Image jschwab1978 Posted - 2 hours ago

$TXG https://finance.yahoo.com/news/10x-genomics-inc-txg-among-001150036.html

User Image WallStreetBuyDip Posted - 17 hours ago

This is the track record showing the results for Small + Mid cap stocks from only buying when H% is low Do you see why I only buy when H% is low? Will next trade $NTLA + $TXG when H% is low for a reversal trade like I did for other small + mid cap stocks. All include timestamps + buy fills for everything. The result speaks for itself.

User Image WallStreetBuyDip Posted - 5 days ago

This is the track record showing the results for Small + Mid cap stocks from only buying when H% is low Do you see why I only buy when H% is low? Will next trade $NTLA + $TXG when H% is low for a reversal trade like I did for other small + mid cap stocks. All include timestamps + buy fills for everything. The result speaks for itself.

User Image nUme22 Posted - 6 days ago

$TXG buy below 12... you have been fairly warned

User Image kellysmith1 Posted - 6 days ago

$TXG what happened to this company..Wow!!

User Image Estimize Posted - 6 days ago

Wall St is expecting -0.29 EPS for $TXG Q4 [Reporting 02/12 AMC] http://www.estimize.com/intro/txg?chart=historical&metric_name=eps&utm_con

User Image John89m Posted - 1 week ago

$TXG two Japanese firms take big position in this!

User Image Powell6531 Posted - 1 week ago

$ENOV $FXH $ROIV $TXG

User Image swingingtech Posted - 1 week ago

$FXH $ROIV $TXG $ENOV https://wallstreetwaves.com/analyst-sets-unexpected-12-month-price-target-for-fxh/

User Image PulseBeat56 Posted - 1 week ago

$NTLA $TXG

User Image WallStreetBuyDip Posted - 1 week ago

This is the track record showing the results for Small + Mid cap stocks from only buying when H% is low Do you see why I only buy when H% is low? Will next trade $NTLA + $TXG when H% is low for a reversal trade like I did for other small + mid cap stocks. All include timestamps + buy fills for everything. The result speaks for itself.

User Image smartkarma Posted - 1 week ago

$TXG | 10x Genomics Inc.: What Are Their Recent Single-Cell & Spatial Technology Advancements? - Major Drivers "10x Genomics, a leading biotechnology company, presented its financial results for the third quarter ended September 30, 2024, during which the..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/10x-genomics-inc-what-are-their-recent-single-cell-spatial-technology-advancements-major-drivers

User Image GakiYoui_Atsu Posted - 1 week ago

WIMI Hologram Cloud( $WIMI) had $5.00 Average Target Price from Evaluate Research DA Davidson Trims Okta ( $OKTA) Target Price to $75.00 Prosperity Bancshares, Inc. ( $PB) Receives $77.27 Consensus Target Price from Analysts Canadian Solar Inc. ( $CSIQ) Receives $23.33 Consensus Target Price from Brokerages 10x Genomics, Inc. ($TXG) Receives $30.60 Consensus Target Price from Analysts

User Image NakadasuTellaria Posted - 2 weeks ago

WIMI Hologram Cloud( $WIMI) had $5.00 Average Target Price from Evaluate Research Kymera Therapeutics, Inc. ( $KYMR) Receives $49.00 Consensus Target Price from Analysts Prosperity Bancshares, Inc. ( $PB) Receives $77.27 Consensus Target Price from Analysts Canadian Solar Inc. ( $CSIQ) Receives $23.33 Consensus Target Price from Brokerages 10x Genomics, Inc. ($TXG) Receives $30.60 Consensus Target Price from Analysts

User Image WallStreetBuyDip Posted - 2 weeks ago

This is the track record showing the results for Small + Mid cap stocks from only buying when H% is low Do you see why I only buy when H% is low? Will next trade $NTLA + $TXG when H% is low for a reversal trade like I did for other small + mid cap stocks. All include timestamps + buy fills for everything. The result speaks for itself.

User Image Thestocktraderhubzee Posted - 10/31/24

WATCHLIST OCT 31 2024.. $RVLV Roth MKM Maintains Buy on Revolve Gr, Raises Price Target to $29 $TXG Goldman Sachs Maintains Sell on 10x Genomics, Lowers Price Target to $14 $LEU B. Riley Securities Maintains Buy on Centrus Energy, Raises Price Target to $126 $MTDR JP Morgan Maintains Overweight on Matador Resources, Lowers Price Target to $71 $VRNS RBC Capital Reiterates Outperform on Varonis Systems, Maintains $65 Price Target

User Image jjmstocks1 Posted - 10/30/24

$TXG -69% YTD .. bottom feeding biotech name, was able to finish above the 10-day & finished the session with an engulfing bullish after their mixed earnings reports .. might have a chance to fill that gap up in the $16.89 to $19.95 window ..

User Image stockslemon Posted - 10/30/24

$NTLA $TXG I believe that very soon we will see this stock soar! ๐Ÿ’ฏ๐Ÿš€๐ŸŽฏ๐Ÿ’ฏ๐Ÿš€๐ŸŽฏ๐Ÿ’ฏ๐Ÿš€๐ŸŽฏ

User Image stockslemon Posted - 10/30/24

$NTLA $PACB $CRSP $TXG ๐Ÿง ๐Ÿ’ฏ๐Ÿš€๐ŸŽฏ๐Ÿ’Ž

User Image Roadey0 Posted - 10/30/24

$TXG

User Image NoRisksNoFun Posted - 10/30/24

$TXG overreaction!

User Image OpenOutcrier Posted - 10/30/24

$TXG (-9.5% pre) 10x Genomics Inc (TXG) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ... https://finance.yahoo.com/news/10x-genomics-inc-txg-q3-071445544.html

User Image origrid Posted - 10/29/24

$TXG why another 8% drop after a disastrous earning report 25% drop?

User Image nUme22 Posted - 10/29/24

$TXG buy below 12

User Image DonCorleone77 Posted - 10/29/24

$TXG 10x Genomics lowers FY24 revenue view to $595M-$605M from $640M-$660M Consensus is for FY24 revenue $636.59M. The updated range represents a 3% decrease from the FY23 revenue at the midpoint.

User Image DonCorleone77 Posted - 10/29/24

$TXG 10x Genomics reports Q3 EPS (30c), consensus (34c) Reports Q3 revenue $151.7M, consensus $158.63M. Cash and cash equivalents were $398.2M as of September 30. "Our results this quarter fell short of our expectations given greater-than-anticipated disruption from the sales restructuring we implemented in the quarter and cautious customer spending. As these dynamics persist, especially under a difficult macro backdrop, our revenue growth this year will be lower than our previous expectations," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Despite these challenges, I am confident that the steps we are taking will enable us to reach more customers, execute consistently across the portfolio and drive the broad democratization of our technologies to reach the full potential of the large opportunity ahead."

User Image AivelX Posted - 10/29/24

๐Ÿ’ก #AivelX After-Hours Earnings Insights (3/3) ๐Ÿงต Earnings breakdown for: TXG, V, VRNS $TXG - Ref.Earnings: 17 Next Day: 53% new high (max 10.4%) vs 53% new low (max -25.6%) 5 Days Later: 65% new highs, 53% new lows Same Week: 55% broke 16.7 (+6.5%) $V - Ref.Earnings: 1224 Next Day: 57% new high (max 28.9%) vs 37% new low (max -23.6%) 5 Days Later: 72% new highs, 48% new lows Same Week: 46% broke 279 (-2%) $VRNS - Ref.Earnings: 108 Next Day: 63% new high (max 34.9%) vs 28% new low (max -21.9%) 5 Days Later: 81% new highs, 41% new lows Same Week: 44% broke 56 (-4.5%) โœ… Follow us for daily earnings updates and stock analysis. #AI #StockMarket #Investing #Earnings

User Image WallStreetBuyDip Posted - 10/28/24

This is the track record showing the results for Small + Mid cap stocks from only buying when H% is low Do you see why I only buy when H% is low? Will next trade $NTLA + $TXG when H% is low for a reversal trade like I did for other small + mid cap stocks. All include timestamps + buy fills for everything. The result speaks for itself.

User Image Estimize Posted - 10/28/24

Wall St is expecting 57.07% YoY EPS growth for $TXG in Q3, up from 39.62% in Q2 [Reporting Tomorrow 10/29 AMC] http://www.estimize.com/intr

Analyst Ratings
Stephens & Co. Overweight Sep 4, 24
Leerink Partners Outperform Sep 3, 24
UBS Neutral Aug 13, 24
Morgan Stanley Overweight Aug 13, 24
Canaccord Genuity Buy Jul 23, 24
Jefferies Buy Jul 22, 24
B of A Securities Neutral Jul 18, 24
JP Morgan Neutral Jul 18, 24
Stifel Buy Jul 16, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Dec 14 Sell 54.77 2,000 109,540 845,446 12/18/23
Wilbur James Chief Commercial Off.. Chief Commercial Officer Nov 22 Sell 43.3367 3,464 150,118 83,342 11/27/23
Hindson Benjamin J. See Remarks See Remarks Nov 22 Sell 43.3367 3,449 149,468 277,338 11/27/23
McAnear Justin J. Chief Financial Offi.. Chief Financial Officer Nov 22 Sell 43.3367 1,679 72,762 97,105 11/27/23
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Nov 22 Sell 43.53 7,480 325,604 847,446 11/27/23
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Sep 14 Sell 49.59 2,000 99,180 862,093 09/18/23
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Aug 22 Sell 45.7811 3,757 172,000 864,093 08/24/23
McAnear Justin J. Chief Financial Offi.. Chief Financial Officer Aug 22 Sell 45.7811 1,678 76,821 98,784 08/24/23
Wilbur James Chief Commercial Off.. Chief Commercial Officer Aug 22 Sell 45.7811 9,699 444,031 101,253 08/24/23
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Aug 14 Sell 50.26 2,000 100,520 867,850 08/16/23
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Jul 19 Sell 60.03 40,000 2,401,200 869,850 07/21/23
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Jul 19 Option 5.04 20,845 105,059 909,850 07/21/23
Hindson Benjamin J. See Remarks See Remarks Jul 19 Sell 60.03 13,940 836,818 284,236 07/21/23
Hindson Benjamin J. See Remarks See Remarks Jul 19 Option 8.26 13,940 115,144 298,176 07/21/23
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Jul 14 Sell 57.99 2,000 115,980 889,005 07/18/23
STUELPNAGEL JOHN R Director Director Jun 05 Sell 54.8894 10,000 548,894 333,736 06/07/23
Hindson Benjamin J. See Remarks See Remarks May 23 Sell 55.06 2,388 131,483 284,236 05/25/23
Wilbur James Chief Commercial Off.. Chief Commercial Officer May 23 Sell 55.0653 316 17,401 110,952 05/25/23
McAnear Justin J. Chief Financial Offi.. Chief Financial Officer May 23 Sell 55.06 1,665 91,675 100,462 05/25/23
Saxonov Serge Chief Executive Offi.. Chief Executive Officer May 19 Sell 55.06 2,602 143,266 893,190 05/23/23
McAnear Justin J. Chief Financial Offi.. Chief Financial Officer Feb 22 Sell 47.7533 1,245 59,453 75,519 02/24/23
Hindson Benjamin J. See Remarks See Remarks Feb 22 Sell 47.7533 1,742 83,186 250,237 02/24/23
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Feb 22 Sell 47.7533 1,941 92,689 909,715 02/24/23
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Nov 22 Sell 34.07 2,676 91,171 974,926 11/23/22
Hindson Benjamin J. See Remarks See Remarks Nov 22 Sell 34.07 2,361 80,439 217,713 11/23/22
McAnear Justin J. Chief Financial Offi.. Chief Financial Officer Nov 22 Sell 34.07 1,626 55,398 76,764 11/23/22
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Sep 12 Option 1.2 11,500 13,800 977,602 09/14/22
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Aug 23 Sell 35.1913 2,715 95,544 966,102 08/25/22
McAnear Justin J. Chief Financial Offi.. Chief Financial Officer Aug 23 Sell 35.1913 987 34,734 58,092 08/25/22
Hindson Benjamin J. See Remarks See Remarks Aug 23 Sell 35.1913 1,292 45,467 186,246 08/25/22
Saxonov Serge Chief Executive Offi.. Chief Executive Officer May 23 Sell 48.7636 2,656 129,516 968,817 05/25/22
McAnear Justin J. Chief Financial Offi.. Chief Financial Officer May 23 Sell 48.7641 967 47,155 59,079 05/25/22
Hindson Benjamin J. See Remarks See Remarks May 23 Sell 48.7636 1,264 61,637 187,538 05/25/22
CRUTCHFIELD BRADFORD Chief Commercial Off.. Chief Commercial Officer May 23 Sell 48.7642 286 13,947 97,237 05/25/22
Kosaraju Sridhar Director Director May 16 Option 11.48 15,000 172,200 18,458 05/17/22
McAnear Justin J. Chief Financial Offi.. Chief Financial Officer May 13 Buy 40.4855 158 6,397 60,046 05/17/22
CRUTCHFIELD BRADFORD Chief Commercial Off.. Chief Commercial Officer May 13 Buy 40.4855 158 6,397 97,523 05/17/22
Hindson Benjamin J. See Remarks See Remarks Feb 22 Sell 78.5944 360 28,294 160,326 02/24/22
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Feb 22 Sell 78.6003 551 43,309 912,742 02/24/22
McAnear Justin J. Chief Financial Offi.. Chief Financial Officer Feb 22 Sell 78.5994 288 22,637 38,531 02/24/22
CRUTCHFIELD BRADFORD Chief Commercial Off.. Chief Commercial Officer Feb 22 Sell 78.5993 288 22,637 97,365 02/24/22
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Feb 08 Option 11.48 3,038 34,876 925,293 02/10/22
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Feb 08 Sell 89.67 12,000 1,076,040 913,293 02/10/22
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Jan 04 Option 11.48 3,037 34,865 937,255 01/06/22
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Jan 04 Sell 142.08 15,000 2,131,200 922,255 01/06/22
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Dec 28 Option 1.2 56,363 67,636 934,218 12/30/21
Hindson Benjamin J. See Remarks See Remarks Dec 28 Option 1.14 113,920 129,869 160,686 12/30/21
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Dec 07 Option 8.26 8,246 68,112 892,855 12/09/21
Saxonov Serge Chief Executive Offi.. Chief Executive Officer Dec 07 Sell 144.79 15,000 2,171,850 877,855 12/09/21
McAnear Justin J. Chief Financial Offi.. Chief Financial Officer Dec 01 Option 5.04 10,000 50,400 48,819 12/03/21